PIERRE FABRE MEDICAMENT Patent applications |
Patent application number | Title | Published |
20160131639 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 05-12-2016 |
20160106861 | AXL ANTIBODY-DRUG CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER - The present invention relates to an antibody-drug conjugate capable of binding to the protein Axl. From one aspect, the invention relates to an antibody-drug conjugate comprising an antibody capable of binding to Axl, said antibody being conjugated to at least one drug which is a pyrrolobenzodiazepme dimer (PBD dimer) drug. The invention also comprises method of treatment and the use of said antibody-drug conjugate for the treatment of cancer. | 04-21-2016 |
20160083420 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS - The present invention concerns a compound of following formula (I) where: —R | 03-24-2016 |
20160082055 | COMPOSITION COMPRISING A COMBINATION OF AN ELDER EXTRACT AND A STRAIN OF LACTOBACILLUS RHAMNOSUS - The present invention concerns a combination of an elder ( | 03-24-2016 |
20160068567 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS - The present invention concerns a compound of following formula (I) where: —R | 03-10-2016 |
20160068566 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS - The present invention concerns a compound of following formula (I): where: —R | 03-10-2016 |
20160046725 | NOVEL ANTIGEN BINDING PROTEINS AND THEIR USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 02-18-2016 |
20160039935 | NOVEL ANTI-cMET ANTIBODY - The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met. The invention finally comprises products and/or compositions comprising such an antibody in combination with other antibodies and/or chemical compounds directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 02-11-2016 |
20160031995 | NOVEL ANTIBODIES FOR THE TREATMENT OF HIV - The present invention relates to novel isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. | 02-04-2016 |
20150376222 | MACROLIDES USEFUL AS ANTICANCER AGENTS - The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C | 12-31-2015 |
20150368258 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS - The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents. | 12-24-2015 |
20150336943 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS - The present invention concerns benzodioxane-piperidine with general formula I: | 11-26-2015 |
20150315132 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS - The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. | 11-05-2015 |
20150313872 | COMBINATION OF A SLOW SODIUM CURRENT BLOCKER AND A SINUS IF CURRENT INHIBITOR, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMBINATION - The present invention relates to the combination of a selective late sodium current blocker and a selective, specific sinus If current inhibitor, and to the pharmaceutical compositions containing said combination. | 11-05-2015 |
20150307613 | NOVEL ANTI-cMET ANTIBODY - The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both is a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. | 10-29-2015 |
20150306056 | USE OF A DHA ESTER FOR PROPHYLACTIC AND/OR CURATIVE TREATMENT OF DREPANOCYTOSIS - The present invention relates to a docosahexaenoic acid ester including an alcohol selected from among the group made up of nicotinol, panthenol, inositol, isosorbide, and isosorbide mononitrate, or one of the pharmaceutically acceptable salts, enantiomers, diastereoisomers, or mixtures thereof, including racemic mixtures, for the use thereof as a drug for the prophylactic and/or curative treatment of drepanocytosis. | 10-29-2015 |
20150291696 | ANTI-cMET ANTIBODY - Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer. | 10-15-2015 |
20150291507 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES - The present invention relates to the docosahexaenoate panthenyl of the following formula: | 10-15-2015 |
20150266880 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk - The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein. | 09-24-2015 |
20150252114 | NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION AND USES THEREOF - The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention. | 09-10-2015 |
20150250780 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 09-10-2015 |
20150239958 | PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY - The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies. | 08-27-2015 |
20150210713 | GRISEOFULVIN DERIVATIVES - The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular in the treatment of cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same. | 07-30-2015 |
20150191443 | GRISEOFULVIN DERIVATIVES - The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular for treating cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same. | 07-09-2015 |
20150190394 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN - The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain. | 07-09-2015 |
20150157620 | LOZENGES WITH MULTIPLE RELEASE KINETICS FOR ACTIVE INGREDIENTS - The present invention relates to a film-coated lozenge intended to dissolve in the oral cavity, comprising a core comprising at least one active ingredient and at least one cooked sugar, and a shell comprising at least one layer comprising at least one active ingredient. | 06-11-2015 |
20140295452 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to a novel antibody capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for this antibody. The invention likewise comprises the use of said antibody, and corresponding processes, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibody for the prognosis or diagnostic of certain cancers. | 10-02-2014 |
20140235692 | USE OF 3-(R)-[3-(2-METHOXYPHENYLTHIO)-2-(S)-METHYLPROPYL]AMINO-3,4-DIHYDRO- - 2H-1,5-BENZOXATHIEPINE FOR PREVENTING AND/OR TREATING CARDIOTOXIC EFFECTS CAUSED BY CHEMOTHERAPY AND/OR RADIATION - The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or a pharmaceutically acceptable salt thereof for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation. | 08-21-2014 |
20140206743 | USE OF 3-(R)-[3-(2-METHOXYPHENYLTHIO)-2-(S)-METHYLPROPYL]AMINO-3,4-DIHYDRO- - 2H-1,5-BENZOXATHIEPINE FOR TREATING CANCER AND IN PARTICULAR FOR PREVENTING AND/OR TREATING CANCER METASTASES - The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of the pharmaceutically acceptable salts thereof for treating cancer and particularly in preventing and/or treating cancerous metastases. | 07-24-2014 |
20140193329 | ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. | 07-10-2014 |
20140186356 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 07-03-2014 |
20140179794 | LEVOMILNACIPRAN-BASED DRUG FOR FUNCTIONAL RECOVERY AFTER ACUTE NEUROLOGICAL EVENTS - The present invention concerns the use of levomilnacipran as medicinal product in functional recovery after a cerebrovascular accident or traumatic brain injury. The pharmaceutical compositions containing levomilnacipran are exclusively those not containing dextromilnacipran to a proportion of more than 5% by weight of the levomilnacipran/dextromilnacipran mixture, to avoid compromising functional recovery due to the alpha1-blocking property of dextromilnacipran. | 06-26-2014 |
20140170677 | USE OF THE ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCER - The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed. | 06-19-2014 |
20140141023 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 05-22-2014 |
20140115727 | NOVEL ANTI-cMET ANTIBODY - The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. | 04-24-2014 |
20140050661 | NOVEL ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 02-20-2014 |
20140038997 | PHARMACEUTICAL COMPOSITION OF VINFLUNINE WHICH IS INTENDED FOR PARENTERAL ADMINISTRATION PREPARATION METHOD THEREOF AND USE OF SAME - The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer. | 02-06-2014 |
20140031362 | TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT - The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent. | 01-30-2014 |
20130316975 | INCLUSION COMPLEXES CONTAINING PIROXICAM, A CYCLODEXTRIN AND ARGININE - The invention relates to a method for preparing a soluble inclusion complex comprising one or several active substances which are hardly soluble in an aqueous medium and are included in one or several host molecules, using the following successive stages: (a) bringing one or several active substances into contact with one or several host molecules; (b) initiating a molecular diffusion stage by bringing a dense pressurized fluid into contact with the mixture obtained in (a) in a static mode in the presence of one or several diffusing agents; (c) recovering the active substance-host molecule molecular complex formed; (d) adding and mixing an interaction agent with the active substance-host molecule molecular complex; (e) recovering the soluble inclusion compound thus formed. The invention also relates to the soluble inclusion compound obtained by the method, particularly a piroxicam-cyclodextrin-arginine compound. | 11-28-2013 |
20130303734 | NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES - The present disclosure relates to novel humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the disclosure relates to novel anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The disclosure also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The disclosure also relates to a method for the preparation of such novel humanized antibodies. | 11-14-2013 |
20130296553 | VINYL QUINUCLIDINE USEFUL AS A SYNTHESIS INTERMEDIATE IN THE PREPARATION OF (R)-MEQUITAZINE - The present invention relates to the use of the vinyl quinuclidine enantiomer (R) of the following formula 2 as a synthesis intermediate in the preparation of (R)-mequitazine. | 11-07-2013 |
20130296222 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN THERAPY - The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations. | 11-07-2013 |
20130273060 | NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF - The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention. | 10-17-2013 |
20130272957 | NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF - The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention. | 10-17-2013 |
20130267520 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS - The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I), where R | 10-10-2013 |
20130183247 | FLUORESCENT CYANINE-POLYAMINE DERIVATIVES AS A DIAGNOSTIC PROBE - The invention relates to fluorescent derivatives of cyanines conjugated with a polyamine group, having formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to the method for preparing said derivatives, diagnostic compositions containing same and the use thereof as a diagnostic probe for the detection of cancer tumours, in particular in vivo. | 07-18-2013 |
20130172360 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT - The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same. | 07-04-2013 |
20130172326 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY - The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C | 07-04-2013 |
20130172289 | METHOD FOR THE PREPARATION OF SODIUM CHONDROITIN SULPHATE - The present invention concerns a method for obtaining sodium chondroitin sulphate from cartilage, notably of avian origin, as well as a sodium chondroitin sulphate preparation. | 07-04-2013 |
20130171067 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS - The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same. | 07-04-2013 |
20130137768 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES - The present invention relates to the docosahexaenoatepanthenyl of the following formula: It also relates to a method for preparing same and to a pharmaceutical composition comprising same and to the use of same in the treatment or the prevention of cardiovascular diseases, in particular atrial fibrillation. | 05-30-2013 |
20130125252 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor. | 05-16-2013 |
20130109844 | ANTI-cMET ANTIBODY | 05-02-2013 |
20130109841 | ANTI-cMET ANTIBODY | 05-02-2013 |
20130109839 | PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY | 05-02-2013 |
20130085144 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT - The present invention relates to a compound of following formula (I): | 04-04-2013 |
20130040928 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS - The present invention relates to compounds having general formula I characterised in that | 02-14-2013 |
20120322678 | NOVEL PHAGE DISPLAY VECTOR - The invention relates to a minimized phage display vector comprising at least a cloning cassette, a phage display cassette and a bacterial cassette, said cloning cassette comprising a nucleic acid sequence encoding a polypeptide corresponding at least to the intra-domain loop of a constant domain of an antibody. It also relates to their uses for the production of libraries of phages, each phage expressing on its surface a binding protein to be screened for its capacity to bind a binding partner. | 12-20-2012 |
20120252889 | POLYKETIDE MOLECULES AS ANTICANCER AGENTS - The present invention relates to a polyketide molecule of the following formula (I): | 10-04-2012 |
20120245170 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT - The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent. | 09-27-2012 |
20120225936 | METHOD FOR PRODUCING TRIPTOLIDE - The invention relates to a method for producing triptolide from a suspension cell culture of | 09-06-2012 |
20120219569 | USE OF AN ANTI-CD151 ANTIBODY IN THE TREATMENT OF CANCER - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r. | 08-30-2012 |
20120208721 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF - The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively. | 08-16-2012 |
20120178678 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS - The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: —R | 07-12-2012 |
20120178120 | MICROPLATE - The present invention relates to a microplate, or microtitration plate, having an invagination consisting of a continuous peripheral channel making it possible to add thereto, in a single introduction step, a liquid acting as an “evaporation curtain”. The invention is also directed to a device comprising such a microplate, to a manufacturing method and to use of such a microplate. | 07-12-2012 |
20120157463 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS - The present invention relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system. | 06-21-2012 |
20120156191 | ANTI-JAM-A ANTIBODIES - The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening. | 06-21-2012 |
20120141563 | PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE ADMINISTERED PARENTERALLY - The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition. | 06-07-2012 |
20120115860 | NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS - The present invention concerns compounds of general formula (1) (I) wherein R | 05-10-2012 |
20120088792 | Pyridin-2-YL Methylamine Derivatives for Treating Opiate Dependence - The invention concerns the use of compounds of general formula (I) | 04-12-2012 |
20120077777 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY - The present invention relates to a compound of following formula (I): | 03-29-2012 |
20120064130 | METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2 - The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO | 03-15-2012 |
20120029013 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS - The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C | 02-02-2012 |
20120022273 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT - The present invention relates to a new process for the preparation of (poly)aminoalkylaminoacetamide derivatives of epipodophyllotoxin and salts thereof, characterised in that it comprises a step of peptide coupling of 4-amino-4′-demethylepipodophyllotoxin with an amine-containing reactant having protecting groups. | 01-26-2012 |
20110319326 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS - The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R | 12-29-2011 |
20110295036 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN - The present invention relates to a method for synthesizing a pharmaceutically acceptable acid addition salt of (1S, 2R)-milnacipran comprising the following successive steps: (a) reaction of phenylacetonitrile and of (R)-epichlorhydrin in the presence of a base containing an alkaline metal, followed by a basic treatment, and then by an acid treatment in order to obtain a lactone; (b) reaction of said lactone with MNEt | 12-01-2011 |
20110262409 | COMPOSITION COMPRISING A COMBINATION OF AN ELDER EXTRACT AND A STRAIN OF L. PARACASEI, L. CASEI, L. BULGARICUS OR S. THERMOPHILUS - The invention relates to a composition comprising a combination of an elder extract ( | 10-27-2011 |
20110183376 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 07-28-2011 |
20110165062 | Use of an anti-cd151 antibody for early treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. | 07-07-2011 |
20110152289 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I) below: Formula (I) and the pharmaceutically acceptable salts thereof, and also to the preparation method thereof and to the uses thereof, especially in the treatment of cancer. | 06-23-2011 |
20110123516 | NITROGENATED DERIVATIVES OF PANCRATISTATIN - The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation. | 05-26-2011 |
20110118266 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS - The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R | 05-19-2011 |
20110117098 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 05-19-2011 |
20110021589 | IMIDAZOLIC COMPOUNDS AND USE THEREOF AS ALPHA-2 ADRENERGIC RECEPTORS - The invention provides methods of treating a memory deficiency in a subject in need of such treatment, where the methods comprise administering to a subject an effective amount of a compound of formula (1): | 01-27-2011 |
20110015221 | PHARMACEUTICAL COMPOSITION OF VINFLUNINE WHICH IS INTENDED FOR PARENTERAL ADMINISTRATION PREPARATION METHOD THEREOF AND USE OF SAME - The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer. | 01-20-2011 |
20110014122 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 01-20-2011 |
20110003705 | NOVEL METHOD FOR GENERATING AND SCREENING AN ANTIBODY LIBRARY - The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer. | 01-06-2011 |
20100286284 | 5-[1'-(DECAHYDRO-7-HYDROXY-1,1,3A,7-TETRAMETHYL-1H-CYCLOPROPA[A]NAPHTHALEN- -4-YL)-3'-METHYLBUTYL]-2,4,6-TRIHYDROXY-1,3-BENZENEDICARBOXALDEHYDE AS MEDICAMENTS - The present invention relates to new compounds of formula (I) and to their use as medicaments. Preferably, the said compounds are used in the preparation of a medicament or food supplement intended for the treatment and/or prevention of ailments or pathologies ensuing from a disorder of the reuptake of the following neurotransmitters: dopamine, serotonin and/or noradrenaline. | 11-11-2010 |
20100280263 | Process for the Synthesis of Anticancer (Poly) Aminoalkylaminoacetamide Derivatives of Epipodophyllotoxin - The present invention describes a new process for the preparation of (poly)aminoalkylaminoacetamide compounds of epipodophyllotoxin useful for their applications in therapeutics as anticancer agents. This process comprises a step of condensation of a primary-amine-containing reactant, whose amine functions are not protected, with β-chloroacetamido-4′-epipodophyllotoxin in a polar aprotic organic solvent. | 11-04-2010 |
20100273752 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS - The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent or treat pathologies involving histamine H4 receptor. | 10-28-2010 |
20100266570 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTICANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B | 10-21-2010 |
20100202975 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS - The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R | 08-12-2010 |
20100196468 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING A HYDROSOLUBLE VINFLUNINE SALT - Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageously in the form of a capsule or tablet. The invention also concerns a method of treating cancer pathology comprising the oral administration of the pharmaceutical composition of the invention. | 08-05-2010 |
20100196465 | STABLE PHARMACEUTICAL COMPOSITION OF A WATER-SOLUBLE VINORELBINE SALT - A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet. | 08-05-2010 |
20100196363 | CANCER TREATMENT COMBINATION THERAPY COMPRISING VINFLUNINE AND TRASTUZUMAB - The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab. | 08-05-2010 |
20100150935 | USE OF AN ANTI-CXCR4 ANTIBODY IN THE TREATMENT OF CANCER - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. | 06-17-2010 |
20100146650 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 06-10-2010 |
20100105897 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE - The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine. | 04-29-2010 |
20100099709 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES FOR TREATING OPIATE DEPENDENCE - The invention concerns the use pf compounds of general formula (I) | 04-22-2010 |
20100093997 | FLUORINATED CATHARANTHINE DERIVATIVES, THEIR PREPARATION AND THEIR UTILISATION AS VINCA DIMERIC ALKALOID PRECURSORS - The fluorinated derivatives of catharanthine according to the invention respond to the general formula I: | 04-15-2010 |
20100092455 | NOVEL ANTI-PROLIFERATION ANTIBODIES - The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. | 04-15-2010 |
20100087473 | FREEZE-DRIED INJECTABLE PHARMACEUTICAL COMBINATION OF SEMISYNTHETIC VINCA ALKALOIDS AND CARBOHYDRATE STABLE AT ROOM TEMPERATURE - This invention relates to pharmaceutical compositions consisting of a semisynthetic derivative of vinca alkaloid, stable at room temperature, in which said derivative is present in the form of a freeze dried product obtained in the presence of at least one carbohydrate. | 04-08-2010 |
20100087392 | COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS - The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax. | 04-08-2010 |
20100063276 | USE OF 10-[(3R)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE FOR THE PREPARATION OF A DRUG HAVING A SELECTIVE INHIBITION OF MUSCARINIC M1, M2, AND M3 RECEPTORS - This invention relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine as well as its pharmaceutically acceptable salts for the preparation of a drug having the particularity of treating or preventing urinary incontinence, by local and/or oral route. | 03-11-2010 |
20100041703 | RAPID DISINTEGRATION MONOLAYER FILM FOR THE ORAL ADMINISTRATION OF ACTIVE SUBSTANCES - Rapid-disintegration monolayer film for the oral administration of active substances, comprising a water-soluble support containing at least one active substance, characterized in that it comprises a polymeric mixture of a hydrophilic film-forming agent formed from a copolymer of polyvinyl alcohol and of polyethylene glycol (PVA-PEG), of an active substance and of a hydrophilic gelling agent. | 02-18-2010 |
20100029703 | ANHYDROUS CRYSTALLINE VINFLUNINE SALTS, METHOD OF PREPARATION AND USE THEREOF AS A DRUG AND MEANS OF VINFLUNINE PURIFICATION - The present invention relates to anhydrous crystalline vinflunine salts obtained with 1 or 2 equivalents of a pharmaceutically acceptable mineral or organic acid [Acid] 1 or 2 in which [Acid] represents hydrobromic, sulfuric, lactic and fumaric acids for the group of water-soluble crystalline salts, and para-toluene sulfonic, benzoic, mandelic and para-hydroxy benzoic acids for the group of relatively insoluble crystalline salts. | 02-04-2010 |
20090325984 | USE OF 1,7-DIMETHYLXANTHINE FOR THE MANUFACTURE OF A NON-ANXIOGENIC PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER - The present invention relates to the use of paraxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder. | 12-31-2009 |
20090324754 | EUCALYPTUS EXTRACT, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF - The present invention relates to the use of a | 12-31-2009 |
20090324600 | Use of an anti-cd151 antibody in the treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. | 12-31-2009 |
20090318709 | PROCESS FOR THE SYNTHESIS OF N-[3-[(2-METHOXYPHENYL] SULFANYL] -2-METHYLPROPYL] -3,4-DIHYDRO-2H-1,5-BENZOXATHIEPIN-3-AMINE. - The invention relates to a new process for the preparation of N-[3-[(2-methoxyphenyl)sulfanyl]-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine. | 12-24-2009 |
20090318555 | Treatment of Vertigo with Acetyl-L-Leucine - The use of acetyl-L-leucine and the pharmaceutically acceptable salts of same for the manufacture of a medicament for the treatment of vertigo and other balance disorders. Advantageously, the acetyl-L-leucine is a 100% mixture. | 12-24-2009 |
20090312354 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. | 12-17-2009 |
20090298908 | DMAE AS SOLE AGENT FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT - The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type. | 12-03-2009 |
20090265797 | Novel Anti-IGF-IR Antibodies and Uses Thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor. | 10-22-2009 |
20090124010 | Peptide Fractions Promoting Growth and Synthesis of Desired Product (S) Into Cell and/or Tissue Culture - The invention relates to preparing and/or supplementing a cell or tissue culture medium. In particular, said invention relates to a serum-free and/or protein-free cell culture medium comprising peptide fractions isolated from rapeseeds, in particular rapeseeds cakes. A method for the production of a cell culture comprising said peptide fractions and for the use thereof is also disclosed. | 05-14-2009 |
20090118507 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives - The present invention concerns the method for preparing (3-chloro-4-fluorophenyl)-(4-fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone of formula (II) by condensation between 5-methyl-pyrimidin-2-methylamine of formula (I) and cyanohydrin of formula (III). | 05-07-2009 |
20090082582 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate - The invention relates to a process for the preparation of compounds of general formula (3) | 03-26-2009 |
20090082447 | Pharmaceutical Compositions Containing Omega 3 Fatty Acids - Pharmaceutical composition comprising a liquid oil rich in omega-3 polyunsaturated fatty acids which is absorbed on a silica-type support. The composition so obtained has the characteristics of a powder when the oil:silica ratio is of the order of 3:1 while at the same time allowing the required daily dose of omega-3 fatty acids to be delivered in one or more unit doses. The composition according to the invention can be used in the manufacture of oral pharmaceutical forms such as hard capsules. | 03-26-2009 |
20090069308 | Novel Use of Antihistamine Agents for the Preventive or Early Treatment of Inflammatory Syndromes, in Particular Those Triggered by Togaviruses - The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. | 03-12-2009 |
20090049935 | Stabilized milnacipran formulation - It is intended to provide a milnacipran formulation which is more stable than a conventionally known milnacipran formulation, and a method of stabilizing a milnacipran formulation. The object could be achieved by using a milnacipran-containing composition in which milnacipran or a salt thereof is allowed to exist in a porous carrier, packing a powder containing milnacipran or a salt thereof in an HPMC capsule, or combining an additive which does not cause an interaction with milnacipran with time. | 02-26-2009 |
20090042876 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors - The present invention relates to inhibitors of protein kinases of formula I: | 02-12-2009 |
20090036367 | Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine - The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B. | 02-05-2009 |
20080317859 | Stabilization of Testosterone Within Transdermal Devices - The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone to androstenedione and other impurities and accordingly ensures storage of said device over periods of up to thirty-six months. | 12-25-2008 |
20080300382 | Immunogenic Complexes, Preparation Method Thereof And Use Of Same In Pharmaceutical Compositions - The invention relates to a method of improving the immunogenicity of an immunogen, antigen or hapten, by means of coupling with a small support peptide. More specifically, the invention relates to a method of preparing an immunogenic complex, as well as the complexes that can be obtained using one such method, and to the use of said complexes as a medicament in order to increase the immunogenicity of an immunogen. The invention comprises, for example, a support peptide which is coupled with a peptide from protein G of the respiratory syncytial virus (RSV) and to the use thereof as a vaccine for the treatment of respiratory infections linked to RSV. | 12-04-2008 |
20080286198 | Novel anti-IGF-IR antibodies and uses thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 11-20-2008 |
20080260828 | STABLE SOLID DISPERSION OF A DERIVATIVE OF VINCA ALKALOID AND PROCESS FOR MANUFACTURING IT - This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000. | 10-23-2008 |